Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.10 Consensus Target Price from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has earned an average rating of “Moderate Buy” from the ten analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $17.10.

A number of research firms have recently commented on ROIV. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Friday, May 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Tuesday, June 18th. Finally, Piper Sandler raised their price target on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th.

Institutional Investors Weigh In On Roivant Sciences

A number of large investors have recently added to or reduced their stakes in ROIV. Rubric Capital Management LP raised its position in Roivant Sciences by 81.0% during the fourth quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company’s stock valued at $213,370,000 after purchasing an additional 8,500,000 shares in the last quarter. Norges Bank purchased a new stake in Roivant Sciences during the fourth quarter valued at about $41,506,000. Vanguard Group Inc. raised its position in Roivant Sciences by 159.1% during the third quarter. Vanguard Group Inc. now owns 5,602,566 shares of the company’s stock valued at $65,438,000 after purchasing an additional 3,440,374 shares in the last quarter. First Trust Advisors LP raised its position in Roivant Sciences by 434.8% during the fourth quarter. First Trust Advisors LP now owns 2,739,438 shares of the company’s stock valued at $30,764,000 after purchasing an additional 2,227,192 shares in the last quarter. Finally, Penn Davis Mcfarland Inc. purchased a new stake in Roivant Sciences during the first quarter valued at about $17,287,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $11.18 on Tuesday. The stock has a fifty day simple moving average of $10.80 and a two-hundred day simple moving average of $10.87. Roivant Sciences has a 1-year low of $8.24 and a 1-year high of $13.24. The firm has a market cap of $8.26 billion, a price-to-earnings ratio of 2.21 and a beta of 1.24. The company has a current ratio of 25.24, a quick ratio of 25.24 and a debt-to-equity ratio of 0.07.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 25.05% and a net margin of 3,484.86%. The business had revenue of $55.10 million during the quarter, compared to analyst estimates of $30.72 million. During the same period in the prior year, the company earned ($0.38) earnings per share. Roivant Sciences’s revenue was up 155.1% compared to the same quarter last year. Analysts anticipate that Roivant Sciences will post -1.12 earnings per share for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.